Innovative research by Rene Bernards, Ph.D., the co-founder of Agendia, Inc., has identified a gene signature that has potential to identify which patients will benefit from tamoxifen therapy. Bernards’ research appears in the journal Cancer Research, published by the American Association for Cancer Research.

READ FULL ARTICLE Curated publisher From Medical News Today